Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP773638.RArAsetdtdD0EJTKOVLMO_8-rAs_apw7ZD5BHby3yg54E130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773638.RArAsetdtdD0EJTKOVLMO_8-rAs_apw7ZD5BHby3yg54E130_provenance.
• NP860016.RAnAZNGZuScVHAx2AYrWhy8njl1LG4FuH-LjE1HRXl7zE130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860016.RAnAZNGZuScVHAx2AYrWhy8njl1LG4FuH-LjE1HRXl7zE130_provenance.
• NP633360.RApXHyZmaCFqvDlS1QS2L1GacKH-ElLbq9zvriTX4MlYo130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP633360.RApXHyZmaCFqvDlS1QS2L1GacKH-ElLbq9zvriTX4MlYo130_provenance.
• assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP827411.RA-1kEHFdiUIeyxHE6Vw7tI7H3poTxs7F6BNFfD-XoPlc130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827411.RA-1kEHFdiUIeyxHE6Vw7tI7H3poTxs7F6BNFfD-XoPlc130_provenance.
• NP536918.RAHVWTLtO3TrOmVuCKzZanh3ZXDS8ARRxZjhAqWl277SI130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP536918.RAHVWTLtO3TrOmVuCKzZanh3ZXDS8ARRxZjhAqWl277SI130_provenance.
• assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP578917.RADEjWgEWI2I2EjMifoiOTDuy3wg3ClQq0ja6nUy2-0NA130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578917.RADEjWgEWI2I2EjMifoiOTDuy3wg3ClQq0ja6nUy2-0NA130_provenance.
• NP363553.RACzKaZ3pc0GgDWxzSrlpLYsobsveWbubF5FiRKnTQe5A130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP363553.RACzKaZ3pc0GgDWxzSrlpLYsobsveWbubF5FiRKnTQe5A130_provenance.
• NP832631.RAqD4mG3F9FnSGfD66tipvFo4tZFY1ydODZcVR0chAXXQ130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP832631.RAqD4mG3F9FnSGfD66tipvFo4tZFY1ydODZcVR0chAXXQ130_provenance.
• NP578915.RAkqBxD9xM_9mFJn7ESZ_5iSomUAychTOA34xYbrhOAec130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578915.RAkqBxD9xM_9mFJn7ESZ_5iSomUAychTOA34xYbrhOAec130_provenance.
• NP578916.RAvHIEoGpRES-YcqO_3JTSUjFHHYrRjxzDB_b-Ik3Ek3I130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578916.RAvHIEoGpRES-YcqO_3JTSUjFHHYrRjxzDB_b-Ik3Ek3I130_provenance.
• NP578918.RApsiWdr-kEHlbN0YVa6bMGQSw7Y0Iz-SKA22OSjDvhNI130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578918.RApsiWdr-kEHlbN0YVa6bMGQSw7Y0Iz-SKA22OSjDvhNI130_provenance.
• NP300148.RAE-Z1WR8Co84usUuq8AMppR-x_SlCdMRiFPcAjh2dgNc130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP300148.RAE-Z1WR8Co84usUuq8AMppR-x_SlCdMRiFPcAjh2dgNc130_provenance.
• NP785896.RA05QPQeKDb2vu6M6_13kWt8PMaXgaN5uRXSSjWZoQIV4130_assertion description "[Gene-specific quantitative multiplex polymerase chain reaction of candidate oncogenes at 1q32.1 (KIF14), 6p22 (E2F3 and DEK), and tumor suppressor genes at 16q22 (CDH11) and 17q21 (NGFR) showed the most common gene gains in RB to be KIF14 in cell lines (80%) and E2F3 in primary tumors (70%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP785896.RA05QPQeKDb2vu6M6_13kWt8PMaXgaN5uRXSSjWZoQIV4130_provenance.